Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]
This edition presents key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial investigating plasma exchange with Grifols’ human albumin solution, Albutein, combined with intravenous immunoglobulin (IVIG).
Business Questions
Business Questions
- How successful do KOLs think that p38 MAP kinase alpha inhibition could prove to be as an approach for treating AD?
- Do the results from the Phase IIa study with neflamapimod confirm its potential activity as a treatment for AD?
- How important will the REVERSE-SD study be in terms of providing a better understanding of neflamapimod’s role as an AD therapy?
- Do KOLs think that Elayta’s mechanism of action is compatible with it having a neuroprotective role in patients with AD?
- Which types of patient are most likely to benefit from treatment with Elayta?
- How do KOLs perceive plasma exchange as a method for reducing the beta-amyloid load in the brains of patients with AD?
- Which factors are likely to influence the extent to which plasma exchange with Albutein/IVIG is utilised as a treatment for AD?
- How do KOLs rate the chances of the AMBAR trial meeting its primary endpoint and plasma exchange therapy with Albutein/IVIG being successfully marketed?
